| Project/Area Number |
22659010
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | University of Shizuoka |
|---|
Principal Investigator |
OKU Naoto 静岡県立大学, 薬学部, 教授 (10167322)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ASAI Tomohiro 静岡県立大学, 薬学部, 講師 (00381731)
SHIMIZU Kosuke 静岡県立大学, 薬学部, 助教 (30423841)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,090,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2010: ¥1,400,000 (Direct Cost: ¥1,400,000)
|
|---|
| Keywords | ドラッグデリバリー / 虚血性疾患 / リポソーム / 薬物送達 / DDS / タムスロシン / 細胞保護効果 / ナノ粒 / 脳梗塞 / 脳虚血再灌流障害 / アシアロエリスロポエチン / ナノ粒子 |
|---|
| Research Abstract |
Brain ischemia/reperfusion injury is a secondary injury occurring after reperfusion. We previously clarified that liposomal DDS enables the delivery of certain drugs to the ischemic site through the disrupted blood-brain barriers after reperfusion. Therefore, we selected two kinds of agents having neuroprotective effect, asialoerythropoietin and FK506, attempted to liposomalize them, and examined the usefulness. The aim of this work is to develop a novel DDS durgs for the treatment of brain ischemia/reperfusion injury.
|
